By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Key Statistics

Ownership: Public

Web Site: Genzyme Corporation
Symbol: GENZ



Medtronic, Inc.  Cardiac Cell Therapy

Cambridge Antibody Technology Group PLC   Antibodies against TGF-ß

Dyax Corp.  Hereditary Angioedema

Company News
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Report Positive New Data From Lemtrada Multiple Sclerosis Trial 9/11/2014 6:08:08 AM
Sanofi (France) (SAN.PA) Aims For M&A With Genzyme Corporation (GENZ) 9/11/2014 6:03:51 AM
Genzyme Corporation (GENZ) Announces Launch Of “Expression Of Hope III” Program To Build Awareness Of Lysosomal Storage Disorders Through Works Of Art 9/10/2014 10:56:11 AM
Genzyme Corporation (GENZ) To Move 500-Employees To New Space In Westborough 9/5/2014 7:00:57 AM
Genzyme Corporation (GENZ)'s New Rare Disease Pill Will Cost Patients $310,250 A Year 9/4/2014 6:19:14 AM
FDA Approves Genzyme Corporation (GENZ)'s Gaucher Disease Pill Cerdelga 8/19/2014 4:24:02 PM
Genzyme Corporation (GENZ) Receives Label Expansion For Lumizyme® (Alglucosidase Alfa) In The United States For The Treatment Of Pompe Disease 8/4/2014 10:50:11 AM
Genzyme Corporation (GENZ)’s Lemtrada Approved In Argentina For Treatment Of Multiple Sclerosis 6/30/2014 8:36:59 AM
Former Genzyme Corporation (GENZ) Subsidiary rEVO Biologics Files For $75 Million IPO 6/30/2014 7:11:44 AM
FDA Will Review Genzyme Corporation (GENZ)'s Lemtrada Resubmission; Agency Action Expected In Q4 2014 5/30/2014 6:27:08 AM